Trending...
- New Dad Battles Leukemia and Wins!
- Indies United is pleased to present our July 2025 book releases
- AAR to announce fourth quarter fiscal year 2025 results on July 16, 2025
CHICAGO--(BUSINESS WIRE)--Esya Labs, which is developing several ground-breaking novel research assays, today has announced that Novartis is among the first companies to use its technology.
Novartis, a global healthcare company, has used a patented assay developed by Esya Labs to accelerate drug discovery efforts for Mucolipidosis Type IV, a rare inherited metabolic disorder characterized by delayed development and vision impairment.
"This is an ideal example of how our technology can be used, and we are delighted to support Novartis in their research," said Dr. Yamuna Krishnan, Co-founder and Chief Scientific Officer of Esya Labs, a startup originally spun out the University of Chicago where Krishnan is a Professor of Chemistry.
"For us, this is only the beginning. Our probes can help in almost all drug discovery efforts where a disease pathway touches an endocytic organelle, including many neurodegenerative diseases and Lysosomal Storage Disorders," explained Dhivya Venkat, Co-Founder and CEO of Esya Labs. "Measuring dysfunctions of lysosomes and seeing the ability of a drug to change or correct the ion composition directly in live cells obtained from patients can shed important light on the potential of small molecules in drug discovery."
More on illi News
Esya's patented probes are based on synthetic DNA strands that have been engineered to function in a specific way. This engineered DNA forms the backbone of the technology, which can create chemical activity maps of live cells – a process that had previously not been possible.
In addition to working in living cells, the company's 10 commercially available sensors have several unique characteristics: the ability to measure two ions at the same time, quantify ion levels (versus simply detecting the presence of certain chemical), and correct for pH driven distortions of ion measurements. This for the first time enables an accurate read of Calcium and Chloride, among other ions within acidic organelles such as the Lysosome.
While the probes are typically targeted at Lysosomes, applicability is broad and, with slight modifications the technology also works with other organelles, such as the Golgi or Mitochondria. The array of chemicals and enzyme activity includes combinations of pH, Chloride, Calcium, Nitric Oxide, and HOCl, enzyme activity of Cathepsin and Thiol-disulfide exchanges, and the measurement of absolute membrane potential.
Esya itself is using its technology to address another significant and unsolved problem: an early and reliable diagnostic for Alzheimer's disease. The company is working on validating the biomarkers it has detected using its technology and ultimately is planning to go to market with a product suite that enables diagnosis, disease monitoring, and personalized therapeutic plans for Alzheimer's disease.
More on illi News
The University of Chicago's Polsky Center for Entrepreneurship and Innovation has been working with Professor Krishnan's group to manage their created intellectual property, while also providing access various programs to support further development.
About Esya Labs
Esya Labs is a precision diagnostics and drug discovery startup spun out of Dr. Yamuna Krishnan's lab at the University of Chicago. The company is developing early, precise and cost-effective diagnostic tools for neurodegenerative diseases by combining patented DNA nanotechnology with artificial intelligence. Its 10 commercially available assays can be used to accelerate drug discovery for Lysosomal Storage Disorders and numerous neurocognitive impairments. For more information, visit www.esyalabs.com.
About the Polsky Center for Entrepreneurship and Innovation at the University of Chicago
The Polsky Center for Entrepreneurship and Innovation applies world-class business expertise from the University of Chicago Booth School of Business to bring new ideas and breakthrough innovations to market. With a 60-person professional staff, the Polsky Center drives the creation of commercial partnerships and new ventures at the University of Chicago and beyond. As a global leader in entrepreneurship education, the Polsky Center provides training for aspiring entrepreneurs and those seeking a career in private equity, venture capital, and entrepreneurship through acquisition. Learn more at polsky.uchicago.edu and follow updates on Twitter @polskycenter.
Fill out the "Get Started with the Polsky Center" form to subscribe to our bi-monthly newsletter, Partners in Innovation, which features the latest research, news, and updates from the Science and Technology team.
Novartis, a global healthcare company, has used a patented assay developed by Esya Labs to accelerate drug discovery efforts for Mucolipidosis Type IV, a rare inherited metabolic disorder characterized by delayed development and vision impairment.
"This is an ideal example of how our technology can be used, and we are delighted to support Novartis in their research," said Dr. Yamuna Krishnan, Co-founder and Chief Scientific Officer of Esya Labs, a startup originally spun out the University of Chicago where Krishnan is a Professor of Chemistry.
"For us, this is only the beginning. Our probes can help in almost all drug discovery efforts where a disease pathway touches an endocytic organelle, including many neurodegenerative diseases and Lysosomal Storage Disorders," explained Dhivya Venkat, Co-Founder and CEO of Esya Labs. "Measuring dysfunctions of lysosomes and seeing the ability of a drug to change or correct the ion composition directly in live cells obtained from patients can shed important light on the potential of small molecules in drug discovery."
More on illi News
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
- Spur Chicago Announces "Mindfulness in eMOTION" Workshop
- Don't Get Left In The Dark: Duracell Urges Americans To Gear Up For A Stormier-Than-Average Season
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
Esya's patented probes are based on synthetic DNA strands that have been engineered to function in a specific way. This engineered DNA forms the backbone of the technology, which can create chemical activity maps of live cells – a process that had previously not been possible.
In addition to working in living cells, the company's 10 commercially available sensors have several unique characteristics: the ability to measure two ions at the same time, quantify ion levels (versus simply detecting the presence of certain chemical), and correct for pH driven distortions of ion measurements. This for the first time enables an accurate read of Calcium and Chloride, among other ions within acidic organelles such as the Lysosome.
While the probes are typically targeted at Lysosomes, applicability is broad and, with slight modifications the technology also works with other organelles, such as the Golgi or Mitochondria. The array of chemicals and enzyme activity includes combinations of pH, Chloride, Calcium, Nitric Oxide, and HOCl, enzyme activity of Cathepsin and Thiol-disulfide exchanges, and the measurement of absolute membrane potential.
Esya itself is using its technology to address another significant and unsolved problem: an early and reliable diagnostic for Alzheimer's disease. The company is working on validating the biomarkers it has detected using its technology and ultimately is planning to go to market with a product suite that enables diagnosis, disease monitoring, and personalized therapeutic plans for Alzheimer's disease.
More on illi News
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
The University of Chicago's Polsky Center for Entrepreneurship and Innovation has been working with Professor Krishnan's group to manage their created intellectual property, while also providing access various programs to support further development.
About Esya Labs
Esya Labs is a precision diagnostics and drug discovery startup spun out of Dr. Yamuna Krishnan's lab at the University of Chicago. The company is developing early, precise and cost-effective diagnostic tools for neurodegenerative diseases by combining patented DNA nanotechnology with artificial intelligence. Its 10 commercially available assays can be used to accelerate drug discovery for Lysosomal Storage Disorders and numerous neurocognitive impairments. For more information, visit www.esyalabs.com.
About the Polsky Center for Entrepreneurship and Innovation at the University of Chicago
The Polsky Center for Entrepreneurship and Innovation applies world-class business expertise from the University of Chicago Booth School of Business to bring new ideas and breakthrough innovations to market. With a 60-person professional staff, the Polsky Center drives the creation of commercial partnerships and new ventures at the University of Chicago and beyond. As a global leader in entrepreneurship education, the Polsky Center provides training for aspiring entrepreneurs and those seeking a career in private equity, venture capital, and entrepreneurship through acquisition. Learn more at polsky.uchicago.edu and follow updates on Twitter @polskycenter.
Fill out the "Get Started with the Polsky Center" form to subscribe to our bi-monthly newsletter, Partners in Innovation, which features the latest research, news, and updates from the Science and Technology team.
Filed Under: Business
0 Comments
Latest on illi News
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Tarp Supply Inc.® Prepares to Celebrate 21 Years of Excellence in the Tarps Industry
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- ALIVE and KICKING: LAUGHTER NEVER GETS OLD has its World Premiere July 11-20 in St. Charles, IL
- AAR to announce fourth quarter fiscal year 2025 results on July 16, 2025
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- New Dad Battles Leukemia and Wins!
- Kefir Comes to NASCAR as Lifeway Foods Races into Hometown Weekend with Driver Josh Bilicki at The Loop 110
- Recession-Proof Startups: What Business Plans Investors Are Actually Funding in 2025
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- City of Chicago Releases Annual Comprehensive Financial Report for Fiscal Year 2024
- Indies United is pleased to present our July 2025 book releases
- Endurance Warranty Earns 2025 Buyer's Choice Awards from ConsumerAffairs Through Verified Customer Reviews
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Naperville: Structure Fire in the 1600 Block of Country Lakes Drive
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT